ATE368853T1 - Zell-selektives abgabe system - Google Patents

Zell-selektives abgabe system

Info

Publication number
ATE368853T1
ATE368853T1 AT03760107T AT03760107T ATE368853T1 AT E368853 T1 ATE368853 T1 AT E368853T1 AT 03760107 T AT03760107 T AT 03760107T AT 03760107 T AT03760107 T AT 03760107T AT E368853 T1 ATE368853 T1 AT E368853T1
Authority
AT
Austria
Prior art keywords
cpp
cell
present
relates
delivery system
Prior art date
Application number
AT03760107T
Other languages
German (de)
English (en)
Inventor
Mattias Haellbrink
Margus Pooga
Madis Metsis
Priit Kogerman
Andreas Valkna
Anne Meikas
Maria Lindgren
Astrid Graeslund
Goeran Eriksson
Claes Oestensson
Metka Budihna
Matjaz Zorko
Anna Elmquist
Ursel Soomets
Pontus Lundberg
Peter Jaerver
Kuelliki Saar
Samir El-Andaloussi
Kalle Kilk
Uelo Langel
Original Assignee
Cepep Ii Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Ii Ab filed Critical Cepep Ii Ab
Application granted granted Critical
Publication of ATE368853T1 publication Critical patent/ATE368853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
AT03760107T 2002-06-18 2003-06-18 Zell-selektives abgabe system ATE368853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
US39178802P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ATE368853T1 true ATE368853T1 (de) 2007-08-15

Family

ID=29738564

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760107T ATE368853T1 (de) 2002-06-18 2003-06-18 Zell-selektives abgabe system

Country Status (8)

Country Link
US (1) US20080234183A1 (enExample)
EP (1) EP1516184B1 (enExample)
JP (1) JP4503435B2 (enExample)
AT (1) ATE368853T1 (enExample)
AU (1) AU2003253125A1 (enExample)
DE (1) DE60315296T2 (enExample)
SE (1) SE0201863D0 (enExample)
WO (1) WO2003106491A2 (enExample)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
AU2001257169C1 (en) * 2000-04-21 2011-06-16 Tufts Medical Center, Inc. G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
WO2005016960A2 (en) 2003-08-14 2005-02-24 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP1512696A1 (en) * 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1750775A2 (en) * 2004-05-04 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1809291A4 (en) * 2004-11-03 2012-04-04 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY
AU2005304963C1 (en) * 2004-11-04 2011-01-06 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
US7741275B2 (en) 2004-12-22 2010-06-22 Lipopeptide Ab Agents and use thereof
AU2006206428B2 (en) 2005-01-18 2009-07-16 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2625183C (en) 2005-10-04 2019-09-03 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US8299214B2 (en) * 2006-03-13 2012-10-30 Keio University Influenza infection-inhibiting peptide, influenza virus infection inhibitor, liposome, and influenza preventive/therapeutic agent
WO2008063315A2 (en) * 2006-10-13 2008-05-29 University Of Southern California C-TERMINAL DOMAIN TRUNCATION OF MGLUR1α BY CALPAIN AND USES THEREOF
SI2341142T1 (sl) * 2006-12-28 2015-03-31 International Institute Of Cancer Immunology, Inc. HLA-A*1101-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
AU2008211854C1 (en) * 2007-01-29 2014-01-23 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
DE102007008596B4 (de) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
JP2010537632A (ja) * 2007-08-29 2010-12-09 タフツ ユニバーシティー 組織及び細胞への核酸、タンパク質、薬物、及びアデノウイルスの送達を向上させるための細胞透過性ペプチドの製造及び使用方法、組成物並びにキット
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
CN101980718A (zh) 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
DE102009043743B4 (de) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
EP2250278B1 (en) * 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
WO2009120993A2 (en) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2285970A4 (en) * 2008-06-03 2011-10-12 Aileron Therapeutics Inc COMPOSITIONS AND METHODS FOR REINFORCING THE CELL TRANSPORT OF BIOMOLECULES
EP2283029A1 (en) * 2008-06-04 2011-02-16 Medical Research Council Peptides
ES2613866T3 (es) 2008-06-12 2017-05-26 Centre For Addiction And Mental Health Composiciones y métodos para modular la interacción y la función del receptor de dopamina D1-D2
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
AU2009294875C1 (en) 2008-09-22 2015-05-14 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
US20140248296A1 (en) * 2008-10-16 2014-09-04 Kathleen Cogan Farinas Sustained drug delivery system
US20110300167A1 (en) * 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
US20110294738A1 (en) * 2008-11-04 2011-12-01 Yong Ren Pthr1 receptor compounds
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102272142A (zh) * 2008-12-23 2011-12-07 帷幄生物技术公司 非遗传修饰性重编程细胞的组合物和方法
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
CA2756927A1 (en) 2009-04-09 2010-10-14 Centre For Addiction And Mental Health Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
GB0910620D0 (en) 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
BRPI1015424B1 (pt) 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2011038002A1 (en) * 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011072292A2 (en) * 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
JP6008838B2 (ja) 2010-04-29 2016-10-19 エータイアー ファーマ， インコーポレイテッド アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US9540680B2 (en) * 2010-06-07 2017-01-10 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis
RU2556800C2 (ru) * 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP2013534525A (ja) * 2010-06-23 2013-09-05 ヴィヴォスクリプト，インコーポレイテッド 心臓疾患の治療のために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8791121B2 (en) 2010-08-12 2014-07-29 New York University Oligooxopiperazines and methods of making and using them
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2013110876A (ru) * 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012078734A2 (en) * 2010-12-08 2012-06-14 The Research Foundation Of State University Of New York Polypeptide derived from calcitonin receptors and methods of use
US20140056811A1 (en) 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
EP2697386B1 (en) 2011-04-08 2017-11-01 Tufts Medical Center, Inc. Pepducin design and use
US9880151B2 (en) * 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
EP2537858A1 (en) 2011-06-20 2012-12-26 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
IN2014MN00357A (enExample) 2011-08-30 2015-06-19 Medical Res Council
EP2755679B1 (en) * 2011-09-13 2017-08-02 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN116549655A (zh) 2011-11-24 2023-08-08 苏州宝时得电动工具有限公司 多肽序列设计及其在多肽介导的siRNA传递中的应用
CN102532565B (zh) * 2011-12-19 2013-08-28 上海交通大学 可降解亚胺类聚阳离子及其合成方法、纳米颗粒
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US9255086B2 (en) 2012-02-16 2016-02-09 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
WO2014001229A2 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Cell penetrating peptides & methods of identifying cell penetrating peptides
PT2880160T (pt) 2012-08-03 2018-12-17 Cedars Sinai Medical Center Isolamento de mutantes que aumentam o tráfego de proteínas para administração de fármacos
EP2708235A1 (en) 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptide antagonists of the vasopressin-2 receptor
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
RU2015123315A (ru) 2012-11-25 2017-01-10 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Пептиды, стимулирующие подкожный адипогенез
ITMI20122263A1 (it) * 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP2784094A1 (en) 2013-03-28 2014-10-01 Commissariat A L'energie Atomique Et Aux Energies Alternatives New uranium-chelating peptides derived from EF-hand calcium-binding motif useful for uranium biodetection and biodecontamination
WO2014155356A1 (en) 2013-03-28 2014-10-02 Commissariat A L'energie Atomique Et Aux Energies Alternatives New uranium-chelating peptides derived from ef-hand calcium-binding motif useful for uranium biodetection and biodecontamination
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2916102A1 (en) * 2013-06-26 2014-12-31 Phylogica Limited Method of monitoring cellular trafficking of peptides
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP2842566A1 (en) 2013-09-03 2015-03-04 Centre National De La Recherche Scientifique Use of arpin a new inhibitor of the arp2/3 complex for the diagnosis and treatment of diseases
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
JP6493216B2 (ja) * 2013-11-05 2019-04-03 味の素株式会社 ペプチドヒドラジド、ペプチドアミド及びペプチドチオエステルの製造方法
JP6865584B2 (ja) * 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
WO2015105957A1 (en) * 2014-01-08 2015-07-16 Shriners Hospitals For Children Pten antagonist peptides and methods of using the same
US10682388B2 (en) * 2014-01-15 2020-06-16 The Board Of Regents Of The University Of Texas System Targeting of PELP1 in cancer therapy
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
EP2905031A1 (en) 2014-02-10 2015-08-12 B Cell Design A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
AU2015240460A1 (en) 2014-04-04 2016-09-15 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle
JP6759109B2 (ja) 2014-05-21 2020-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｒａｓ抑制性ペプチドおよびその使用
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
EP3374386B1 (en) 2015-11-13 2024-05-29 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
US12050215B2 (en) * 2015-11-17 2024-07-30 The Regents Of The University Of Michigan Macromolecular structures and uses thereof
CA3017424A1 (en) * 2016-03-15 2017-09-21 Idp Discovery Pharma, S.L. Peptides with anti-cancer activity
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
WO2018013912A1 (en) * 2016-07-15 2018-01-18 The Board Of Regents Of The University Of Oklahoma Anti-arid3a treatments for inflammatory disorders
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
KR102557126B1 (ko) 2016-12-07 2023-07-18 몰레큘러 템플레이츠, 인코퍼레이션. 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자
NZ756012A (en) 2017-01-17 2025-10-31 Michael David Forrest Therapeutic inhibitors of the reverse mode of atp synthase
EP3360891B1 (en) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Cell penetrating peptides of human origin
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
KR102095284B1 (ko) * 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CN111386042B (zh) * 2017-12-04 2023-01-31 热生物制品有限公司 基于细胞的疫苗的生产
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
WO2019210267A2 (en) * 2018-04-27 2019-10-31 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
EP3817776A4 (en) * 2018-07-02 2022-11-30 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
KR20210064254A (ko) * 2018-09-26 2021-06-02 가부시키가이샤 가네카 세포막 투과성 펩티드
CN113453723A (zh) * 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
CN118079011A (zh) 2019-02-01 2024-05-28 利兰斯坦福初级大学董事会 用于将核酸递送至肺部的分解性细胞穿透复合物
AU2020218940B2 (en) * 2019-02-04 2025-08-28 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US12338268B2 (en) * 2019-03-05 2025-06-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating protein aggregation-associated diseases
WO2021004539A1 (zh) 2019-07-11 2021-01-14 厦门大学 用于胞内递送分子的复合物
WO2021016330A2 (en) 2019-07-22 2021-01-28 Oneskin, Inc. Polypeptides having anti-senescent effects and uses thereof
TWI889695B (zh) * 2019-08-02 2025-07-11 西班牙商Ｉｄｐ發現製藥公司 黑色素細胞調節胜肽
EP4061833A4 (en) * 2019-11-22 2023-09-06 Alcamen Stem Cell Therapeutics, LLC COMPOSITIONS AND METHODS FOR DEREPRESSION OF RE1 SILENCING TRANSCRIPTION FACTOR TARGET GENES
WO2021113434A1 (en) 2019-12-03 2021-06-10 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth
JP7640976B2 (ja) 2019-12-31 2025-03-06 シァメン・ユニヴァーシティ 分子の細胞内送達用の多量体化送達システム
EP3906935A1 (en) 2020-05-06 2021-11-10 Sorbonne Universite Peptides for preventing or treating viral infections
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
CA3206148A1 (en) 2021-01-24 2022-07-28 Michael David FORREST Therapeutic modifiers of the reverse mode of atp synthase
WO2022212513A1 (en) * 2021-03-31 2022-10-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
EP4320234A2 (en) 2021-04-07 2024-02-14 Astrazeneca AB Compositions and methods for site-specific modification
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
KR102504190B1 (ko) * 2021-06-03 2023-02-28 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
KR102793149B1 (ko) * 2021-11-24 2025-04-09 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
KR102819567B1 (ko) * 2021-11-24 2025-06-13 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
CN114349846B (zh) * 2022-01-07 2023-12-15 天津市泌尿外科研究所 一种人精子膜蛋白or1d2特异性多肽与抗体的制备方法
US20250289849A1 (en) * 2022-03-23 2025-09-18 Council Of Scientific & Industrial Research Peptide to treat alpha-synuclein amyloid based disorders
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
EP4626477A1 (en) 2022-12-01 2025-10-08 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
WO2025172421A1 (en) 2024-02-14 2025-08-21 Astrazeneca Ab Compositions and methods for treatment of huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291074C (en) * 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP1037649B1 (en) * 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP2002531113A (ja) * 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
WO2001097830A1 (en) * 2000-06-22 2001-12-27 Mount Sinai School Of Medicine Modification of mdm2 activity
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
NZ524386A (en) * 2000-08-25 2005-10-28 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
ATE466069T1 (de) * 2000-09-05 2010-05-15 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
FR2818981A1 (fr) * 2001-01-03 2002-07-05 Synt Em Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules
AU2002240201A1 (en) * 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2003064453A2 (de) * 2002-01-27 2003-08-07 Viromics Gmbh Trojanische inhibitoren, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
WO2003106491A2 (en) 2003-12-24
JP4503435B2 (ja) 2010-07-14
HK1078130A1 (en) 2006-03-03
EP1516184A2 (en) 2005-03-23
US20080234183A1 (en) 2008-09-25
JP2006514602A (ja) 2006-05-11
EP1516184B1 (en) 2007-08-01
SE0201863D0 (en) 2002-06-18
DE60315296D1 (de) 2007-09-13
WO2003106491A3 (en) 2004-12-23
AU2003253125A1 (en) 2003-12-31
AU2003253125A8 (en) 2003-12-31
DE60315296T2 (de) 2008-04-17

Similar Documents

Publication Publication Date Title
DE60315296D1 (de) Zell-selektives Abgabe System
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
GEP20125594B (en) Sclerostin binding agents
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
ATE398630T1 (de) Zyklische conotoxin-peptide
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
ATE409040T1 (de) Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
TW200508249A (en) Antibodies for the cancer specific antigen
ATE360644T1 (de) Vegf-peptide und deren verwendung
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
EP1801232A4 (en) METHOD FOR SCREENING A TRANSMEMBRANENZYMHEMMSTOFFS
WO2010133806A3 (fr) Peptides marques et leur utilisation pour le dosage d'irap circulant
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
SE0202608D0 (sv) New sequences
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II
DE60327467D1 (de) Mss4 als antifungisches zielmolekül
UA90682C2 (en) Variant fc regions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties